{"id":"etanercept-etn","safety":{"commonSideEffects":[{"rate":"37","effect":"Injection site reactions (erythema, itching, pain)"},{"rate":"29","effect":"Upper respiratory tract infections"},{"rate":"12","effect":"Headache"},{"rate":"2-3","effect":"Serious infections (tuberculosis, opportunistic infections)"},{"rate":null,"effect":"Demyelinating disease"},{"rate":null,"effect":"Congestive heart failure exacerbation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Etanercept consists of the extracellular ligand-binding portion of the human TNF receptor II fused to the Fc region of human IgG1. It acts as a soluble TNF receptor that competitively binds TNF-alpha and TNF-beta, preventing their interaction with cell-surface TNF receptors and thereby suppressing the inflammatory cascade. This mechanism reduces the production of inflammatory mediators and decreases immune cell activation.","oneSentence":"Etanercept is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor (TNF), a key inflammatory cytokine.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:29:47.659Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Psoriatic arthritis"},{"name":"Ankylosing spondylitis"},{"name":"Juvenile idiopathic arthritis"},{"name":"Plaque psoriasis"},{"name":"Crohn's disease"}]},"trialDetails":[{"nctId":"NCT06654882","phase":"PHASE3","title":"Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis","status":"RECRUITING","sponsor":"Duke University","startDate":"2026-01-09","conditions":"Polyarticular Course Juvenile Idiopathic Arthritis (JIA)","enrollment":400},{"nctId":"NCT03997786","phase":"PHASE2, PHASE3","title":"A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Pharmaceutical Industries Limited","startDate":"2020-01-15","conditions":"Moderate-to-severe Chronic Plaque Psoriasis","enrollment":135},{"nctId":"NCT02840175","phase":"PHASE3","title":"Treatment Tapering in JIA With Inactive Disease","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-05-18","conditions":"Juvenile Idiopathic Arthritis","enrollment":62},{"nctId":"NCT04870203","phase":"PHASE3","title":"Combination of Baricitinib and Anti-TNF in Rheumatoid Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University Hospital, Bordeaux","startDate":"2021-07-15","conditions":"Rheumatoid Arthritis","enrollment":160},{"nctId":"NCT00508547","phase":"","title":"Psoriasis Longitudinal Assessment and Registry","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Scientific Affairs, LLC","startDate":"2007-06-21","conditions":"Psoriasis","enrollment":15842},{"nctId":"NCT03451851","phase":"PHASE3","title":"A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneously Administered Guselkumab for the Treatment of Chronic Plaque Psoriasis in Pediatric Participants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2018-07-11","conditions":"Psoriasis","enrollment":120},{"nctId":"NCT04066348","phase":"PHASE2","title":"TNF-α Treatment of Blast-Induced Tinnitus","status":"RECRUITING","sponsor":"Wayne State University","startDate":"2022-07-01","conditions":"Tinnitus, Noise Induced","enrollment":88},{"nctId":"NCT06016517","phase":"","title":"Application of the Personalized N-of-1 Trial Design in Patients With Rheumatoid Arthritis","status":"NOT_YET_RECRUITING","sponsor":"Tufts Medical Center","startDate":"2026-03-15","conditions":"Arthritis, Rheumatoid","enrollment":18},{"nctId":"NCT05950724","phase":"EARLY_PHASE1","title":"RENAL: TNF-alpha Inhibitor for Improving Renal Dysfunction and Primary Graft Dysfunction After Lung Transplant","status":"ENROLLING_BY_INVITATION","sponsor":"Northwestern University","startDate":"2023-09-17","conditions":"Lung Transplant; Complications","enrollment":20},{"nctId":"NCT07386587","phase":"PHASE3","title":"Methotrexate Alone vs Methotrexate + Etanercept for Minimal/Low Disease Activity in Juvenile Idiopathic Arthritis","status":"ENROLLING_BY_INVITATION","sponsor":"University of Child Health Sciences and Children's Hospital, Lahore","startDate":"2026-01-27","conditions":"Juvenile Idiopathic Arthritis","enrollment":60},{"nctId":"NCT05305066","phase":"NA","title":"Stand UP to Rheumatoid Arthritis (SUPRA)","status":"RECRUITING","sponsor":"Marie Hudson, MD","startDate":"2023-02-01","conditions":"Rheumatoid Arthritis","enrollment":75},{"nctId":"NCT06075706","phase":"PHASE2","title":"Trial of Efficacy and Safety of MC0518 Versus Best Available Therapy in Participants With Steroid-Refractory Acute Graft Versus Host Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"medac GmbH","startDate":"2023-11-13","conditions":"Steroid-refractory Acute Graft-versus-host Disease","enrollment":48},{"nctId":"NCT01000441","phase":"PHASE4","title":"Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2009-12-23","conditions":"Rheumatoid Arthritis","enrollment":300},{"nctId":"NCT07352566","phase":"PHASE4","title":"Utilization of a Microdevice for Psoriasis and Atopic Dermatitis","status":"NOT_YET_RECRUITING","sponsor":"University of California, San Francisco","startDate":"2026-01-01","conditions":"Psoriasis, Atopic Dermatitis","enrollment":10},{"nctId":"NCT03585946","phase":"","title":"Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis","status":"WITHDRAWN","sponsor":"Massachusetts General Hospital","startDate":"2030-01-01","conditions":"Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis, Drug Reaction","enrollment":""},{"nctId":"NCT02987257","phase":"PHASE3","title":"NATIENS: Optimal Management and Mechanisms of SJS/TEN","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2023-03-21","conditions":"Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses","enrollment":2},{"nctId":"NCT05891600","phase":"","title":"A Study to Learn About the Adherence and Clinical Outcomes in Colombian Patients With an E-Device for Etanercept Administration in Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Pfizer","startDate":"2024-06-06","conditions":"Rheumatoid Arthritis","enrollment":60},{"nctId":"NCT02030613","phase":"NA","title":"Effective Dose of Etanercept in Patients Treated for Juvenile Idiopathic Arthritis","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2013-10-01","conditions":"Juvenile Idiopathic Arthritis","enrollment":126},{"nctId":"NCT02829424","phase":"PHASE4","title":"Multicenter Randomized Double Blind Controlled-study to Assess the Potential of Methotrexate Versus Placebo to Improve and Maintain Response to Anti TNF- Alpha Agents in Adult Patients With Moderate to Severe Psoriasis","status":"TERMINATED","sponsor":"Assistance Publique Hopitaux De Marseille","startDate":"2017-01-23","conditions":"Psoriasis","enrollment":78},{"nctId":"NCT03792841","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC","status":"TERMINATED","sponsor":"Amgen","startDate":"2019-02-05","conditions":"Metastatic Castration-resistant Prostate Cancer, Prostate Cancer","enrollment":212},{"nctId":"NCT05379322","phase":"PHASE3","title":"The Use of Synovial Biopsies in Predicting Response to Biologic Therapy in Rheumatoid Arthritis Patients","status":"WITHDRAWN","sponsor":"Abu Dhabi Stem Cells Center","startDate":"2023-03-01","conditions":"Rheumatoid Arthritis","enrollment":""},{"nctId":"NCT06392074","phase":"PHASE1","title":"A Study Investigating the Safety, Absorption, and Elimination of MB04, a New Compound That May Potentially be Used in the Treatment of Autoimmune Disorders","status":"COMPLETED","sponsor":"mAbxience Research S.L.","startDate":"2024-03-07","conditions":"Healthy Volunteers","enrollment":141},{"nctId":"NCT04585711","phase":"PHASE1","title":"Pharmacokinetics and Pharmacodynamics of Biologic Drugs in Obese Patients With Arthritis","status":"WITHDRAWN","sponsor":"Duke University","startDate":"2026-07-01","conditions":"Juvenile Idiopathic Arthritis, Rheumatoid Arthritis, Obesity","enrollment":""},{"nctId":"NCT07184853","phase":"NA","title":"Ruxolitinib Plus Etanercept vs Ruxolitinib for Steroid-Refractory Severe Acute GVHD","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2025-09-25","conditions":"Graft vs Host Disease","enrollment":122},{"nctId":"NCT03294954","phase":"PHASE1","title":"GD2 Specific CAR and Interleukin-15 Expressing Autologous NKT Cells to Treat Children With Neuroblastoma","status":"RECRUITING","sponsor":"Baylor College of Medicine","startDate":"2018-01-18","conditions":"Neuroblastoma","enrollment":70},{"nctId":"NCT07149792","phase":"PHASE4","title":"A Multi-center RCT Clinical Trial on Personalized Precision Medicine for Patients With Psoriasis and Psoriatic Arthritis and Investigation on Cardiovascular Biomarkers","status":"RECRUITING","sponsor":"Taichung Veterans General Hospital","startDate":"2025-07-29","conditions":"Psoriasis, Psoriasis Arthritis, Biologics","enrollment":50},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":"Rheumatic Disease","enrollment":80},{"nctId":"NCT04985435","phase":"PHASE4","title":"Better After CHoosing. Randomly Allocated or Patient Preference Based Treatment With Filgotinib or TNFi in RA (BACH)","status":"RECRUITING","sponsor":"R.Bos","startDate":"2021-05-12","conditions":"Rheumatoid Arthritis","enrollment":100},{"nctId":"NCT03414502","phase":"PHASE3","title":"Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response","status":"RECRUITING","sponsor":"University of Nebraska","startDate":"2007-12-10","conditions":"Rheumatoid Arthritis","enrollment":400},{"nctId":"NCT04891640","phase":"NA","title":"Biologic Abatement and Capturing Kids' Outcomes and Flare Frequency in Juvenile Spondyloarthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"Children's Hospital of Philadelphia","startDate":"2021-11-11","conditions":"Juvenile Spondyloarthritis","enrollment":164},{"nctId":"NCT03915964","phase":"PHASE4","title":"A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-04-25","conditions":"Rheumatoid Arthritis","enrollment":2663},{"nctId":"NCT04086745","phase":"PHASE4","title":"A Study of Baricitinib in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-02-14","conditions":"Rheumatoid Arthritis","enrollment":1317},{"nctId":"NCT07041112","phase":"","title":"Ten-Year Biologic Drug Survival in Psoriasis: Role of Genetic and Cardiometabolic Predictors","status":"COMPLETED","sponsor":"Juan Ruano Ruiz","startDate":"2012-01-01","conditions":"Psoriasis, Psoriatic Arthritis (PsA), Cardiovascular Risk Factors","enrollment":1000},{"nctId":"NCT06707194","phase":"PHASE4","title":"Effect and Safety of Benzathine Penicillin Combined With Etanercept on Spondyloarthritis","status":"RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2025-06-14","conditions":"Spondyloarthritis (SpA), Ankylosing Spondylitis (AS)","enrollment":340},{"nctId":"NCT02713997","phase":"PHASE4","title":"Anti-inflammatory Therapy to Improve Outcomes After TPIAT","status":"COMPLETED","sponsor":"University of Minnesota","startDate":"2016-12","conditions":"Pancreatitis, Chronic; Diabetes; Transplant","enrollment":43},{"nctId":"NCT03649061","phase":"PHASE4","title":"COBRA-Slim With or Without Fast Access to TNF Blockade for Remission Induction in Early RA","status":"COMPLETED","sponsor":"P. Verschueren","startDate":"2018-06-08","conditions":"Arthritis, Rheumatoid","enrollment":276},{"nctId":"NCT05080218","phase":"PHASE4","title":"COVID-19 VaccinE Response in Rheumatology Patients","status":"COMPLETED","sponsor":"Jeffrey Curtis","startDate":"2021-11-15","conditions":"Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis","enrollment":841},{"nctId":"NCT04571697","phase":"","title":"A Study of Comparing Rates of Dementia and Alzheimer's Disease in Participants Initiating Methotrexate Versus Those Initiating Anti-tumor Necrosis Factor (TNF)-Alpha Therapy","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2020-09-28","conditions":"Dementia, Alzheimer Disease","enrollment":34647},{"nctId":"NCT06596772","phase":"PHASE3","title":"A Study to Compare Efficacy, Pharmacokinetics, Safety and Immunogenicity of MB04 [proposed Etanercept Biosimilar] to Enbrel® [EU-sourced] in Rheumatoid Arthritis","status":"RECRUITING","sponsor":"mAbxience Research S.L.","startDate":"2024-10-03","conditions":"Rheumatoid Arthritis (RA)","enrollment":458},{"nctId":"NCT02714634","phase":"PHASE4","title":"Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide","status":"RECRUITING","sponsor":"University Hospital, Strasbourg, France","startDate":"2016-03-30","conditions":"Rheumatoid Arthritis, Insufficient Response to Methotrexate or Leflunomide","enrollment":286},{"nctId":"NCT04973566","phase":"PHASE1","title":"A Study of Nipocalimab With Co-administration of Etanercept or Hydroxychloroquine in Healthy Participants","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2021-08-31","conditions":"Healthy","enrollment":48},{"nctId":"NCT04254627","phase":"PHASE1","title":"TNF and Glucocorticoid Antagonist for GWI Associated Multi-symptom Disease Homeostasis Reset","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nova Southeastern University","startDate":"2021-09-24","conditions":"Gulf War Illness","enrollment":20},{"nctId":"NCT01848028","phase":"","title":"PsoBest - The German Psoriasis Registry","status":"RECRUITING","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2008-01","conditions":"Psoriasis, Psoriatic-arthritis","enrollment":3500},{"nctId":"NCT04118556","phase":"PHASE2","title":"Decidua Stroma Cells for Steroid Resistent Acute Graft-versus-host Disease After Allo-HSCT","status":"RECRUITING","sponsor":"Mats Remberger","startDate":"2021-12-01","conditions":"GVHD, Acute","enrollment":50},{"nctId":"NCT01706692","phase":"","title":"Swiss Dermatology Network of Targeted Therapies (SDNTT)","status":"RECRUITING","sponsor":"Swiss Dermatology Network for Targeted Therapies","startDate":"2011-02","conditions":"Psoriasis","enrollment":1121},{"nctId":"NCT03976245","phase":"PHASE4","title":"Advanced Therapeutics in Rheumatoid Arthritis (RA)","status":"RECRUITING","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2020-03-01","conditions":"Rheumatoid Arthritis","enrollment":144},{"nctId":"NCT06011889","phase":"PHASE2, PHASE3","title":"Study of the Efficacy and Safety of Etanercept Treatment in Patients With SAPHO Syndrome","status":"RECRUITING","sponsor":"National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland","startDate":"2024-09-04","conditions":"SAPHO Syndrome","enrollment":60},{"nctId":"NCT03445845","phase":"PHASE4","title":"Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2018-12-14","conditions":"Axial Spondyloarthritis","enrollment":300},{"nctId":"NCT02308163","phase":"PHASE3","title":"A Study to Evaluate Safety and Efficacy of ASP015K in Patients With Rheumatoid Arthritis (RA) Who Had an Inadequate Response to DMARDs","status":"COMPLETED","sponsor":"Astellas Pharma Inc","startDate":"2014-08-08","conditions":"Rheumatoid Arthritis","enrollment":509},{"nctId":"NCT01932372","phase":"","title":"Tofacitinib (Xeljanz) Special Investigation for Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-07-26","conditions":"Rheumatoid Arthritis","enrollment":9968},{"nctId":"NCT00679042","phase":"PHASE3","title":"Islet Transplantation in Type 1 Diabetic Patients Using the University of Illinois at Chicago (UIC) Protocol","status":"ACTIVE_NOT_RECRUITING","sponsor":"CellTrans Inc.","startDate":"2007-09-05","conditions":"Type 1 Diabetes Mellitus","enrollment":21},{"nctId":"NCT06585384","phase":"PHASE1","title":"Safety of a Strategy Combining Etanercept Administration with Repeated Contrast Ultrasound in Patients with Alzheimer's Disease","status":"NOT_YET_RECRUITING","sponsor":"Fondation Ophtalmologique Adolphe de Rothschild","startDate":"2025-03","conditions":"Alzheimer Disease","enrollment":5},{"nctId":"NCT03728478","phase":"PHASE3","title":"STep-up and Step-down Therapeutic Strategies in Childhood ARthritiS","status":"RECRUITING","sponsor":"Istituto Giannina Gaslini","startDate":"2019-05-29","conditions":"Oligoarthritis, Juvenile, Polyarthritis, Juvenile, Rheumatoid Factor Negative","enrollment":260},{"nctId":"NCT04485325","phase":"PHASE4","title":"Capability of Tofacitinib or Etanercept to Accelerate Tapering of NSAID and Treat-to-target Guided De-escalation of Corticosteroids in RA Patients","status":"COMPLETED","sponsor":"Dr. Frank Behrens","startDate":"2019-11-04","conditions":"Rheumatic Arthritis","enrollment":92},{"nctId":"NCT06563635","phase":"","title":"Frequency of Tuberculosis in Psoriasis Patients","status":"COMPLETED","sponsor":"Bezmialem Vakif University","startDate":"2023-05-01","conditions":"Psoriasis Vulgaris, Tuberculosis","enrollment":719},{"nctId":"NCT04725422","phase":"","title":"CHronic Nonbacterial Osteomyelitis International Registry","status":"RECRUITING","sponsor":"Seattle Children's Hospital","startDate":"2018-08-01","conditions":"Chronic Nonbacterial Osteomyelitis, Chronic Recurrent Multifocal Osteomyelitis","enrollment":2000},{"nctId":"NCT03182426","phase":"PHASE1, PHASE2","title":"Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2017-08-15","conditions":"Diabetes Mellitus, Type 1","enrollment":22},{"nctId":"NCT02451748","phase":"PHASE4","title":"IL-7 and IL-7R Expression in RA Patients With Active vs. Inactive Disease Treated With DMARD or CIMZIA","status":"COMPLETED","sponsor":"University of Illinois at Chicago","startDate":"2015-08","conditions":"Rheumatoid Arthritis","enrollment":32},{"nctId":"NCT05281614","phase":"EARLY_PHASE1","title":"Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D","status":"COMPLETED","sponsor":"Benaroya Research Institute","startDate":"2022-09-21","conditions":"Type 1 Diabetes","enrollment":20},{"nctId":"NCT01903317","phase":"","title":"Evaluation of Vitamin D Levels in Psoriasis Patients","status":"WITHDRAWN","sponsor":"University of California, Irvine","startDate":"2013-06","conditions":"Psoriasis","enrollment":""},{"nctId":"NCT01965132","phase":"","title":"Korean College of Rheumatology Biologics and Targeted Therapy Registry","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2012-12-01","conditions":"Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis","enrollment":10000},{"nctId":"NCT03839862","phase":"","title":"Faecal Analyses in Spondyloarthritis Therapy","status":"RECRUITING","sponsor":"Region Skane","startDate":"2019-01-01","conditions":"Spondyloarthropathies, Ankylosing Spondylitis","enrollment":50},{"nctId":"NCT01793519","phase":"PHASE4","title":"Stopping TNF Alpha Inhibitors in Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Georgetown University","startDate":"2013-01","conditions":"Rheumatoid Arthritis","enrollment":290},{"nctId":"NCT00979771","phase":"PHASE2","title":"A Study to Investigate the Ability of GSK706769 to Maintain Clinical Remission After Withdrawal of Enbrel in Rheumatoid Arthritis Patients","status":"WITHDRAWN","sponsor":"GlaxoSmithKline","startDate":"2010-02-01","conditions":"Arthritis, Rheumatoid","enrollment":""},{"nctId":"NCT05115903","phase":"PHASE4","title":"Biologic Tapering Study of TNF Inhibitors in Axial Spondyloarthritis","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2021-12-01","conditions":"Axial Spondyloarthritis","enrollment":15},{"nctId":"NCT04912401","phase":"","title":"the Efficacy and Safety of Etanercept （Yi Sai Pu) in Chinese Patients With Moderate-to-Severe Psoriasis","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2020-12-04","conditions":"Psoriasis, Etanercept","enrollment":100},{"nctId":"NCT02464878","phase":"PHASE2","title":"Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2017-01","conditions":"Kidney Transplant, Type 1 Diabetes","enrollment":2},{"nctId":"NCT00393471","phase":"PHASE3","title":"Study Comparing Etanercept Plus Methotrexate to Either Etanercept or Methotrexate Alone in Rheumatoid Arthritis.","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2000-10","conditions":"Active Rheumatoid Arthritis","enrollment":615},{"nctId":"NCT05702879","phase":"","title":"Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success","status":"UNKNOWN","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-09-06","conditions":"Ulcerative Colitis","enrollment":240},{"nctId":"NCT04251741","phase":"PHASE4","title":"Using Adalimumab Serum Concentration to Choose a Subsequent Biological DMARD in Rheumatoid Arthritis Patients Failing Adalimumab Treatment","status":"UNKNOWN","sponsor":"Reade Rheumatology Research Institute","startDate":"2020-07-31","conditions":"Rheumatoid Arthritis","enrollment":86},{"nctId":"NCT03636373","phase":"PHASE4","title":"Pilot Study Evaluating The Efficacy Of Etanercept In Acute Gout","status":"TERMINATED","sponsor":"Rutgers, The State University of New Jersey","startDate":"2019-10-25","conditions":"Gout Attack","enrollment":5},{"nctId":"NCT02471144","phase":"PHASE3","title":"Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2015-09-29","conditions":"Chronic Severe Plaque-type Psoriasis","enrollment":162},{"nctId":"NCT00116272","phase":"","title":"Organization of Teratology Information Services (OTIS) Autoimmune Diseases in Pregnancy Project","status":"COMPLETED","sponsor":"Amgen","startDate":"2005-04","conditions":"Pregnancy","enrollment":830},{"nctId":"NCT00585650","phase":"PHASE1, PHASE2","title":"Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet","status":"COMPLETED","sponsor":"University of California, Irvine","startDate":"2007-05","conditions":"Psoriasis","enrollment":20},{"nctId":"NCT00686595","phase":"PHASE4","title":"A Study to Evaluate the Switch From Etanercept to Infliximab in Subjects With Moderate-to-Severe Psoriasis (Study P05133)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-10-01","conditions":"Psoriasis","enrollment":48},{"nctId":"NCT05925166","phase":"NA","title":"Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ Fusion Protein in the Treatment of Acute Gout","status":"NOT_YET_RECRUITING","sponsor":"Lihua Duan","startDate":"2023-09-01","conditions":"Acute Gout","enrollment":100},{"nctId":"NCT04267614","phase":"","title":"This Study is to Investigate the Effect of Etanercept in Early Versus Delayed Referral for Management of Rheumatoid Arthritis Patients.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-11-01","conditions":"Arthritis Rheumatoid","enrollment":1226},{"nctId":"NCT05871086","phase":"PHASE2, PHASE3","title":"Coenzyme Q10 in Juvenile Idiopathic Arthritis Patients","status":"UNKNOWN","sponsor":"Nourhan Elsherif","startDate":"2023-05-01","conditions":"Juvenile Idiopathic Arthritis","enrollment":60},{"nctId":"NCT00224393","phase":"PHASE2","title":"Phase II Trial of Enbrel in Patients With Primary Systemic Amyloidosis","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2001-02","conditions":"Primary Systemic Amyloidosis","enrollment":60},{"nctId":"NCT02144857","phase":"PHASE4","title":"Effects of Treatment With Biological Agents on Vascular and Cardiac Function in Psoriasis","status":"UNKNOWN","sponsor":"University of Athens","startDate":"2014-05-30","conditions":"Psoriasis","enrollment":200},{"nctId":"NCT00841789","phase":"PHASE2","title":"A Randomized, Double Blind, Placebo Controlled Study of Etanercept in Children With Kawasaki Disease","status":"COMPLETED","sponsor":"Michael Portman","startDate":"2009-03","conditions":"Mucocutaneous Lymph Node Syndrome, Kawasaki Disease","enrollment":205},{"nctId":"NCT00730392","phase":"PHASE1, PHASE2","title":"Etanercept in New Onset Type 1 Diabetes","status":"COMPLETED","sponsor":"State University of New York at Buffalo","startDate":"2002-10","conditions":"Type 1 Diabetes","enrollment":18},{"nctId":"NCT05696106","phase":"","title":"Risk of Incident IMID in Patients Treated With Biologics and Immunosuppressive Drugs for a Single IMID","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-04-02","conditions":"Inflammatory Disease","enrollment":750000},{"nctId":"NCT04559412","phase":"PHASE1","title":"Study to Assess the Safety and Efficacy of Enbrel Administered by Sofusa DoseConnect for Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Sorrento Therapeutics, Inc.","startDate":"2021-03-15","conditions":"Rheumatoid Arthritis","enrollment":11},{"nctId":"NCT02913261","phase":"PHASE3","title":"Safety and Efficacy of Ruxolitinib Versus Best Available Therapy in Patients With Corticosteroid-refractory Acute Graft vs. Host Disease After Allogeneic Stem Cell Transplantation","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-03-10","conditions":"Corticosteroid Refractory Acute Graft vs Host Disease","enrollment":310},{"nctId":"NCT02373813","phase":"PHASE3","title":"Study of Etanercept Monotherapy vs Methotrexate Monotherapy for Maintenance of Rheumatoid Arthritis Remission","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-02-20","conditions":"Rheumatoid Arthritis","enrollment":371},{"nctId":"NCT01421069","phase":"PHASE3","title":"Extension Study Evaluating Etanercept in 3 Subtypes of Childhood Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2011-10-10","conditions":"Juvenile Idiopahtic Arthritis","enrollment":109},{"nctId":"NCT04610476","phase":"PHASE3","title":"Impact of Tapering Immunosuppressants on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis","status":"UNKNOWN","sponsor":"University of Erlangen-Nürnberg Medical School","startDate":"2020-10-19","conditions":"Psoriatic Arthritis, Withdrawal, Reduction","enrollment":270},{"nctId":"NCT02374021","phase":"PHASE4","title":"Treatments Against RA and Effect on FDG-PET/CT","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2016-07","conditions":"Arthritis, Rheumatoid","enrollment":159},{"nctId":"NCT05567380","phase":"","title":"Comparative Study of Janus Kinase (JAK) Inhibitors Vs Tumor Necrosis Factor (TNF) Inhibitors in Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2022-10","conditions":"Rheumatoid Arthritis","enrollment":150},{"nctId":"NCT02620189","phase":"","title":"Th17 Responses Evaluated in RA Patients on Inhibitors of TNFα","status":"COMPLETED","sponsor":"Queen Mary University of London","startDate":"2015-03","conditions":"Rheumatoid Arthritis","enrollment":60},{"nctId":"NCT02376790","phase":"PHASE3","title":"Etanercept and Methotrexate in Combination or as Monotherapy in Psoriatic Arthritis","status":"COMPLETED","sponsor":"Amgen","startDate":"2015-03-03","conditions":"Psoriatic Arthritis","enrollment":851},{"nctId":"NCT03100253","phase":"PHASE4","title":"Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGation","status":"TERMINATED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2018-03-01","conditions":"Rheumatoid Arthritis","enrollment":208},{"nctId":"NCT01219257","phase":"","title":"Longitudinal ULtrasonographic Study of Patients With Spondylarthritis Starting Biological Therapy","status":"COMPLETED","sponsor":"Diakonhjemmet Hospital","startDate":"2011-09","conditions":"Spondyloarthritis, Ultrasonography","enrollment":50},{"nctId":"NCT05320159","phase":"","title":"Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-02-03","conditions":"Psoriasis","enrollment":17743},{"nctId":"NCT04798287","phase":"","title":"Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2021-03-10","conditions":"Rheumatoid Arthritis","enrollment":105711},{"nctId":"NCT05424393","phase":"","title":"Real-World Study on Long-term Treatment With YISAIPU for Fujian RA Patients","status":"UNKNOWN","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2022-03-04","conditions":"Rheumatoid Arthritis","enrollment":500},{"nctId":"NCT03033095","phase":"NA","title":"Prediction of the Answer to the Treatment by Biotherapies for Naive Spondyloarthritis by Combinatorial Analysis of Serum Biomarkers","status":"COMPLETED","sponsor":"University Hospital, Grenoble","startDate":"2016-07","conditions":"Spondylitis, Ankylosing","enrollment":50},{"nctId":"NCT04399382","phase":"","title":"A Clinical Study to Evaluate the Efficacy of Biologics in SpA","status":"UNKNOWN","sponsor":"The University of Hong Kong-Shenzhen Hospital","startDate":"2022-01-12","conditions":"Spondyloarthritis (SpA)","enrollment":40},{"nctId":"NCT05379049","phase":"","title":"Therapeutic Response to Tumor Necrosis Factor-alpha (TNF-alpha) Antagonists in Rheumatoid Arthritis.","status":"UNKNOWN","sponsor":"University of Sulaimani","startDate":"2022-03-01","conditions":"Rheumatoid Arthritis, Inflammatory Arthritis, Ankylosing Spondylitis","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":418,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Enbrel"],"phase":"marketed","status":"active","brandName":"Etanercept (ETN)","genericName":"Etanercept (ETN)","companyName":"University of Leeds","companyId":"university-of-leeds","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Etanercept is a TNF receptor fusion protein that binds and neutralizes tumor necrosis factor (TNF), a key inflammatory cytokine. Used for Rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}